WO2004037266A1 - Composes pour le traitement de la toux - Google Patents

Composes pour le traitement de la toux Download PDF

Info

Publication number
WO2004037266A1
WO2004037266A1 PCT/EP2003/011759 EP0311759W WO2004037266A1 WO 2004037266 A1 WO2004037266 A1 WO 2004037266A1 EP 0311759 W EP0311759 W EP 0311759W WO 2004037266 A1 WO2004037266 A1 WO 2004037266A1
Authority
WO
WIPO (PCT)
Prior art keywords
phenyl
methyl
hydrogen
alkyl
cough
Prior art date
Application number
PCT/EP2003/011759
Other languages
English (en)
Inventor
Christine Charman
John R. Fozard
Original Assignee
Novartis Ag
Novartis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag, Novartis Pharma Gmbh filed Critical Novartis Ag
Priority to AU2003274067A priority Critical patent/AU2003274067A1/en
Publication of WO2004037266A1 publication Critical patent/WO2004037266A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents

Definitions

  • This invention relates to organic compounds and, in particular to their use as pharmaceuticals.
  • the invention provides, in one aspect, use of a compound of formula I
  • R 1 is phenyl that is unsubstituted or is substituted by 1, 2 or 3 substituents selected from the group halogen, C ⁇ -C -alkyl, trifluoromethyl, hydroxy and C ⁇ -C -alkoxy, R 2 is hydrogen or C ⁇ -C7-alkyl,
  • R 3 is hydrogen, C ⁇ -C 7 -alkyl or phenyl that is unsubstituted or is substituted by 1, 2 or 3 substituents selected from the group halogen, C ⁇ -C7-alkyl, trifluoromethyl, hydroxy and C 1 -C7- alkoxy,
  • R 4 is phenyl that is unsubstituted or is substituted by 1, 2 or 3 substituents selected from the group halogen, Ci-Cyalkyl, trifluoromethyl, hydroxy and Ci-Cyalkoxy; or is naphthyl, 1H- indol-3-yl or l-C ⁇ -C7-alkyl-indol-3-yl,
  • R 5 and R 6 are each independently of the other hydrogen or C ⁇ -C 7 -alkyl, at least one of R 5 and R 6 being hydrogen, and R 7 is C 3 -C8-cycloalkyl, D-azacycloheptan-2-on-3-yl or L-azacycloheptan-2-on-3-yl.
  • the invention provides, in another aspect, a method of treating cough, in a subject, particularly a human subject, in need of such treatment, which comprises administering to said subject an effective amount of a compound of formula I as hereinbefore defined.
  • Treatment of cough in accordance with the invention may be symptomatic.
  • Cough to be treated in accordance with the invention includes conditions associated with an action that occurs as the result of irritation of the throat, larynx and airways. It takes the form of a noisy expulsion of air, and its function is to clear the airways of the substances causing the irritation anything from particles of dust to smoke, chemicals, and virus-laden mucus. Cough may be due to one or more underlying diseases including chronic obstructive pulmonary disease (COPD), upper respiratory tract infections (UR ⁇ ), postnasal drip, acute viral infection, asthma, lung cancer, interstitial lung disease, gastroesophageal reflux disease (GERD), angiotensin converting enzyme-induced cough and heart failure.
  • COPD chronic obstructive pulmonary disease
  • UR ⁇ upper respiratory tract infections
  • postnasal drip postnasal drip
  • acute viral infection asthma
  • lung cancer interstitial lung disease
  • gastroesophageal reflux disease GEF
  • angiotensin converting enzyme-induced cough and heart failure angiotensin converting enzyme-
  • C ⁇ -C7-alkyl is, for example, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, neopentyl, n-hexyl or n-heptyl, preferably C ⁇ -C 4 alkyl, especially methyl or ethyl, and more especially methyl.
  • Halogen is, for example, fluorine, chlorine, bromine or iodine.
  • Halophenyl is, for example, (fluoro-, chloro-, bromo- or iodo-)phenyl, preferably fluorophenyl or chlorophenyl, especially 4-fluorophenyl or 4-chlorophenyl, and more especially 4-chlorophenyl.
  • Dihalophenyl is, for example, dichlorophenyl, difluorophenyl or chlorofluorophenyl, preferably dichlorophenyl or difluorophenyl, especially 3,4-dichlorophenyl or 3,4- difluorophenyl, and more especially 3,4-dichlorophenyl.
  • Trihalophenyl is, for example, trifluorophenyl or trichlorophenyl.
  • l-C ⁇ -C7-alkyl-indol-3-yl is, for example, l-methyl-indol-3-yl.
  • C 3 -C 8 -Cycloalkyl - and analogously C5-C7-cycloalkyl - is in each case a cycloalkyl radical having the number of ring carbon atoms indicated.
  • C.-Cs-Cycloalkyl is therefore, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl or cyclooctyl, preferably cyclohexyl.
  • D-Azacycloheptan-2-on-3-yl corresponds to the following group
  • the compounds of formula I may be of formula IA
  • Compounds of formula IA are usually preferred for use in accordance with the invention.
  • Compounds of formula I having a basic group may, for example, form acid addition salts with suitable mineral acids, such as hydrohalic acids, sulfuric acid or phosphoric acid, for example hydrochlorides, hydrobromides, sulfates, hydrogen sulfates or phosphates.
  • suitable mineral acids such as hydrohalic acids, sulfuric acid or phosphoric acid, for example hydrochlorides, hydrobromides, sulfates, hydrogen sulfates or phosphates.
  • corresponding salts with bases are also possible, for example corresponding alkali metal or alkaline earth metal salts, for example sodium, potassium or magnesium salts, or salts with ammonia or organic amines, for example ammonium salts.
  • the invention relates preferably to the use of compounds of formula I wherein
  • R 1 is phenyl, 3,5-bistrifluoromethyl-phenyl or 3,4,5-trimethoxyphenyl,
  • R 2 is hydrogen or C ⁇ -C7-alkyl
  • R 3 is hydrogen or phenyl
  • R 4 is phenyl, halo-phenyl, dihalo-phenyl, trihalo-phenyl, 2-naphthyl, lH-indol-3-yl or 1-C ⁇ -
  • R 5 and R 6 are each independently of the other hydrogen or C ⁇ -C7-alkyl, at least one of R 5 and R 6 being hydrogen, and
  • R 7 is C5-C7cycloalkyl, D-azacycloheptan-2-on-3-yl or L-azacycloheptan-2-on-3-yl.
  • the invention relates especially to the use of compounds of formula I wherein
  • R 1 is 3,5-bistrifluoromethyl-phenyl
  • R 2 is hydrogen, methyl or ethyl
  • R 3 is hydrogen or phenyl
  • R 4 is phenyl, 4-chlorophenyl, 4-fluorophenyl, 3,4-dichloro-phenyl, 3,4-difluoro-phenyl, 3- fluoro-4-chloro-phenyl, 3,4,5-trifluoro-phenyl, 2-naphthyl, lH-indol-3-yl or 1 -methyl -indol-
  • R 5 and R 6 are each independently of the other hydrogen or methyl, at least one of R s and R 6 being hydrogen, and
  • R 7 is cyclohexyl, D-azacycloheptan-2-on-3-yl or L-azacycloheptan-2-on-3-yl.
  • the invention relates more especially to the use of compounds of formula I wherein
  • R 1 is 3,5-bistrifluoromethyl-phenyl
  • R 2 is hydrogen or methyl
  • R 3 is hydrogen or phenyl
  • R 4 is phenyl, 4-chlorophenyl, 3,4-dichloro-phenyl, 2-naphthyl, lH-indol-3-yl or 1 -methyl - indol-3-yl,
  • R 5 and R 6 are hydrogen
  • R 7 is cyclohexyl, D-azacycloheptan-2-on-3-yl or L-azacycloheptan-2-on-3-yl. Special mention should be made of each of the following sub-groups of a group of compounds of formula I:
  • the invention relates most importantly to the use of (4R)-4-[N'-methyl-N'-(3,5-bistrifluoro- methylbenzoyl)amino]-4-(3,4-dichlorobenzyl)-but-2-enoic acid N-[(R)-epsilon-caprolactam- 3-yl]-amide, i.e. a compound of formula II
  • the compounds of formula I in free or pharmaceutically acceptable salt form, may be prepared as described in WO 98/07694 or WO 01/85696. As mentioned therein, they may be in the form of their hydrates and/or may include other solvents, for example solvents which may have been used for the crystallisation of compounds in solid form.
  • the compounds of formula I may be obtained in the form of mixtures of stereoisomers, for example mixtures of diastereoisomers or mixtures of enantiomers, such as racemates, or possibly also in the form of pure stereoisomers.
  • Mixtures of diastereoisomers obtainable in accordance with the process or by some other method can be separated in customary manner into mixtures of enantiomers, for example racemates, or into individual diastereoisomers, for example on the basis of the physico-chemical differences between the constituents in known manner by fractional crystallisation, distillation and/or chromatography.
  • the more active isomer is isolated.
  • Mixtures of enantiomers, especially racemates, obtainable in accordance with the process or by some other method can be separated into the individual enantiomers by known methods, for example by recrystallisation from an optically active solvent, with the aid of microorganisms, by chromatography and/or by reaction with an optically active auxiliary compound, for example a base, acid or alcohol, to form mixtures of diastereoisomeric salts or functional derivatives, such as esters, separation thereof and freeing of the desired enantio- mer.
  • an optically active auxiliary compound for example a base, acid or alcohol
  • compounds of formula I in free form or in pharmaceutically acceptable salt form, may be administered by any appropriate route, for example orally, e.g. in tablet, capsule or liquid form, parenterally, for example in the form of an injectable solution or suspension, or intranasally, for example in the form of an aerosol or other atomisable formulation using an appropriate intranasal delivery device, e.g. a nasal spray such as those known in the art, or by inhalation. Oral administration is however preferred.
  • the compound of formula I in free or salt form may be administered in a pharmaceutical composition together with a pharmaceutically acceptable diluent or carrier.
  • a pharmaceutical composition may be as described in WO 98/07694, for example dry powders, tablets, capsules, liquids, injection solutions, infusion solutions or inhalation suspensions as described in Examples A to E of WO 98/07694, or may be prepared using other formulating ingredients and techniques known in the art.
  • the dosage of the compound of formula I in free or salt form can depend on various factors, such as the activity and duration of action of the active ingredient, the severity of the condition to be treated, the mode of administration, the species, sex, ethnic origin, age and weight of the subject and/or its individual condition.
  • the daily dose for administration for example oral administration, to a warm-blooded animal, particularly a human being, weighing about 75 kg is estimated to be from approximately 1 mg to approximately 1000 mg, especially from approximately 5 mg to approximately 200 mg. That dose may be administered, for example, in a single dose or in several part doses of, for example, from 5 to 200 mg.
  • the suitability of a compound of formula I for the treatment of cough may be tested by determining the inhibitory effect of a compound of formula I on cough induced by release of endogenous neuropeptides in guinea pigs.
  • Unanaesthetised, unrestrained male Dunkin Hartley guinea pigs 250-500 g are placed individually in a transparent plastic whole body plethysmograph (Buxco, USA) and baseline airway function measured for 2 minutes.
  • the guinea pigs are exposed to a nebulised (DeVilbiss ultrasonic, USA) aqueous solution of citric acid (0.6 M) for 10 minutes.
  • the compound of formula I (0.3, 3.0 or 10.0 mg/kg) or vehicle (2% dimethylsulfoxide (DMSO), 1:5 CREMOPHOR El ⁇ saline) are dosed orally 2 hours prior to the 10 minute citric acid (0.6 M) challenge. Animals are not selected but rather randomly assigned to different groups. Each drug treatment group is further sub-divided into different groups for the different doses. All experiments have appropriate time matched controls. Values are given as means + s.e. mean. For statistical differences the data is analysed using ANONA and post-hoc Tukey's test, with a P value ⁇ 0.05 taken as significant.
  • Cough is measured as follows: the plethysmograph chamber is fitted with a microphone and connected to both an external speaker and a computer. The animals are continuously watched by an observer who counts the number of coughs. The criteria for cough are the characteristic high sound with the mouth open, which is readily distinguished from a sneeze. During cough there is a quick large abdominal movement which is detected as a transient increase in airflow over and above the normal flow.
  • Cough is measured using this method during the 10 minutes exposure and for a further 5 minutes following exposure.

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne l'utilisation d'un composé de formule générale (I), sous forme libre ou sous forme de sel acceptable du point de vue pharmaceutique pour la préparation d'un médicament destiné au traitement de la toux, dans laquelle R1, R2, R3, R4, R5, R6 et R7 ont la signification indiquée dans la description.
PCT/EP2003/011759 2002-10-24 2003-10-23 Composes pour le traitement de la toux WO2004037266A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003274067A AU2003274067A1 (en) 2002-10-24 2003-10-23 Compounds for the treatment of cough

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0224788.0 2002-10-24
GBGB0224788.0A GB0224788D0 (en) 2002-10-24 2002-10-24 Organic compounds

Publications (1)

Publication Number Publication Date
WO2004037266A1 true WO2004037266A1 (fr) 2004-05-06

Family

ID=9946528

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2003/011759 WO2004037266A1 (fr) 2002-10-24 2003-10-23 Composes pour le traitement de la toux

Country Status (4)

Country Link
AU (1) AU2003274067A1 (fr)
GB (1) GB0224788D0 (fr)
TW (1) TW200418488A (fr)
WO (1) WO2004037266A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006045820A1 (fr) * 2004-10-27 2006-05-04 Laboratori Guidotti S.P.A. Compositions pharmaceutiques a base d'antagonistes de nk2 pour usage pediatrique

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996026183A1 (fr) * 1995-02-22 1996-08-29 Novartis Ag Composes 1-aryl-2-acylamino-ethane et leur utilisation en tant qu'antagonistes des neurokinines et notamment des neurokinines 1
WO1998007694A1 (fr) * 1996-08-22 1998-02-26 Novartis Ag Derives d'acylaminoalkenylene comme antagonistes de nk1 et nk2
WO2002051440A1 (fr) * 2000-12-22 2002-07-04 Takeda Chemical Industries, Ltd. Medicaments de combinaison

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996026183A1 (fr) * 1995-02-22 1996-08-29 Novartis Ag Composes 1-aryl-2-acylamino-ethane et leur utilisation en tant qu'antagonistes des neurokinines et notamment des neurokinines 1
WO1998007694A1 (fr) * 1996-08-22 1998-02-26 Novartis Ag Derives d'acylaminoalkenylene comme antagonistes de nk1 et nk2
WO2002051440A1 (fr) * 2000-12-22 2002-07-04 Takeda Chemical Industries, Ltd. Medicaments de combinaison
EP1352659A1 (fr) * 2000-12-22 2003-10-15 Takeda Chemical Industries, Ltd. Medicaments de combinaison

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
GAO Z ET AL: "Recent advances in neurokinin receptor antagonists", CURRENT MEDICINAL CHEMISTRY 1999 NETHERLANDS, vol. 6, no. 5, 1999, pages 375 - 388, XP009024134, ISSN: 0929-8673 *
GERSPACHER M ET AL: "Dual neurokinin NK1/NK2 antagonists: N-[(R,R)-(E)-1-arylmethyl-3-(2- oxo-azepan-3-yl)carbamoyl]allyl-N-methyl-3,5- bis(trifluoromethyl)benzamides and 3-[N'-3,5- bis(trifluoromethyl)benzoyl-N-arylmethyl-N'-methylhydrazino]-N-[(R)- 2-oxo-azepan-3-yl]propionamides", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, OXFORD, GB, vol. 11, no. 23, 2001, pages 3081 - 3084, XP002240091, ISSN: 0960-894X *
YASUMITSU R ET AL: "Effects of specific tachykinin receptor antagonists on citric acid-induced cough and bronchoconstriction in unanesthetized guinea pigs.", EUROPEAN JOURNAL OF PHARMACOLOGY. NETHERLANDS 11 APR 1996, vol. 300, no. 3, 11 April 1996 (1996-04-11), pages 215 - 219, XP002267169, ISSN: 0014-2999 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006045820A1 (fr) * 2004-10-27 2006-05-04 Laboratori Guidotti S.P.A. Compositions pharmaceutiques a base d'antagonistes de nk2 pour usage pediatrique
EA012264B1 (ru) * 2004-10-27 2009-08-28 Лаборатори Гуидотти С.П.А. Фармацевтические композиции, основанные на антагонистах nk2, для применения в педиатрической практике
US7727955B2 (en) 2004-10-27 2010-06-01 Laboratori Guidotti S.P.A. Pharmaceutical compositions based on NK2 antagonists for pediatric use
NO338586B1 (no) * 2004-10-27 2016-09-12 Laboratori Guidotti Spa Anvendelse av tachykininantagonist for fremstilling av farmasøytiske formuleringer, oral farmasøytisk sammensetning for pediatrisk anvendelse, og matprodukt omfattende nevnte farmasøytiske sammensetning

Also Published As

Publication number Publication date
AU2003274067A1 (en) 2004-05-13
GB0224788D0 (en) 2002-12-04
TW200418488A (en) 2004-10-01

Similar Documents

Publication Publication Date Title
US20230159453A1 (en) Inhibitors of norovirus and coronavirus replication
US9707206B2 (en) Mast cell stabilizers treatment for systemic disorders
CN103764633A (zh) 3,5 -二氨基-6-氯-n-（n-（4 -（4 -（2 -（己基（2,3,4,5,6 -五羟基己基）氨基）乙氧基）苯基）丁基）甲脒基）吡嗪-2-甲酰胺
CN105073717A (zh) 可用于治疗由黏膜水化不足造成的疾病的氯-吡嗪甲酰胺衍生物
US20060083714A1 (en) Combination of a pde iv inhibitor and a tnf-alpha antagonist
AU2008259864C1 (en) Methods and compositions for administration of Oxybutynin
JP2005539042A (ja) 呼吸器疾患、アレルギー性疾患、喘息及びｃｏｐｄを処置するためのグルココルチコイド及びｐｄｅ−４−阻害剤の新規組合せ
CN104955812A (zh) 经芳烷基和芳氧基烷基取代的上皮钠通道阻断化合物
JP2023524693A (ja) ラクトフェリンの投与によるＳＡＲＳ－ＣｏＶ－２ウイルス侵入の阻害およびその使用
US20180110774A1 (en) Compositions and methods for treatment of pulmonary hypertension
WO2004037266A1 (fr) Composes pour le traitement de la toux
CN104302648A (zh) 琥珀酸盐的晶形
US20050203164A1 (en) Use of acylaminoalkenylene-amide derivatives in functional motility disorders of the viscera
US20080004296A1 (en) Organic Compounds
US20230226056A1 (en) Compatible solutes for preventing or treating sars-cov-2 infections
CN111803635B (zh) 小分子抑制剂在治疗呼吸道病毒性肺炎上的应用
US20230270709A1 (en) Antiviral pharmaceutical composition for topical administration
EP4201404A1 (fr) Composés antiviraux à utiliser dans le traitement d'une infection à coronavirus
WO2023034282A1 (fr) Utilisations de propanolol pour la gestion d'infections virales
EP4271477A1 (fr) <sup2/>? <sub2/>?4?inhibition double du virus sars-cov-2 du montélukast antagoniste du récepteur de leucotriène ltd
WO2022212365A1 (fr) Nucléosides de pyrrolopyrimidine pour le traitement ou la prévention d'une infection par sras-cov-2
US20060014835A1 (en) Therapeutic agent for chronic obstructive pulmonary disease
JP2000290198A (ja) 鼻腔抵抗上昇等の抑制剤
CA2543552A1 (fr) Utilisation d'antagonistes de la neurokinine dans le traitement de l'enuresie
JPH03206050A (ja) 医薬組成物

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LT LU LV MA MD MK MN MX NI NO NZ OM PG PH PL PT RO RU SC SE SG SK SY TJ TM TN TR TT UA US UZ VC VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP